Lakewood-Amedex Biotherapeutics reports release available on Nu-3 gel preclinical safety data

Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc.

LABT

0.00
  • Lakewood-Amedex Biotherapeutics posted preclinical safety data supporting dose selection for a planned Phase 2a trial of Nu-3 gel.
  • Nu-3 was well tolerated at doses above planned Phase 2a levels, with very low systemic exposure.
  • The company is preparing a Phase 2a study in infected diabetic foot ulcers using 2%, 5%, 10% gel concentrations.
  • Press release: https://lakewoodamedex.com/


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607150802PR_NEWS_USPR_____NY04764) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.